Gangliosides enable hepatitis A to infect hepatocytes
Researchers use CRISPR-Cas9 gene-editing to establish gangliosides are invoved in hepatitis A entering liver cells, revealing a potential drug target.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers use CRISPR-Cas9 gene-editing to establish gangliosides are invoved in hepatitis A entering liver cells, revealing a potential drug target.
The stem cells in-depth focus includes articles on using computational approaches to expand the applications of stem cell therapies and how organoids could be used to speed up the drug discovery process with a focus on retinal disease.
The articles in this in-depth focus discuss the difficulties in deciding what information to capture when imaging three-dimensional (3D) cell models and the use of non-invasive imaging techniques to discover small molecule drugs to control protein translation.
This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
A team used both structural and spectroscopic techniques to study the dynamics of cell surface G-protein coupled receptors (GPCRs).
The researchers revealed the mechanism by which signalling becomes dysfunctional in upper motor neuron (UMN) diseases, such as amyotrophic lateral sclerosis (ALS).
Find several chemical formulas for potential COVID-19 therapeutics and drug targets currently in development here.
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
Researchers have found that antibodies produced in response to SARS and COVID-19 are cross-reactive, but not cross protective in cells and mice.
A new article has outlined the body's inflammatory response to COVID-19 infection, saying that lipid mediators derived from omega-3 fatty acids could prevent life-threatening inflammation.